Search

Dr Ashley Wood and Vera Silva from Cardiff University join our My Macular and Me webinar to discuss new research into early age-related macular degeneration (AMD). Dr Wood’s team is developing technology to detect early changes in vision, especially difficulties adjusting to low light, which could help diagnose AMD sooner.

New research has found that taking a daily vitamin and mineral supplement can slow the progression of late-stage dry age-related macular degeneration (AMD), otherwise known as geographic atrophy (GA).

Professor Richard Gale covers all the exciting developments for wet and dry AMD, as well as diabetic macular oedema. From recently approved treatments in the UK to the growing role of biosimilars, you can find out about the progress being made. Professor Gale will also reveal what’s in the pipeline, and why there’s reason to feel hopeful for the future as we move into 2025 and beyond.

Lytenava (bevacizumab gamma), is the first licensed version of Avastin for wet age-related macular degeneration. The treatment was approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS last year.

There are so many low vision aids (LVAs) on the market, making it difficult to know which one is right for you. But what really works? And which devices offer the best improvements to quality of life for those living with macular disease? 

Current treatments for wet age-related macular degeneration (AMD) have been life changing for many, helping to maintain vision. However, not all patients respond well to anti-VEGF injections, highlighting the need for alternative treatments. Professor Dulcie Mulholland and PhD student Elisha Griffin have been exploring whether 'homoisoflavonoids', found in rare hyacinth plants, could help prevent abnormal blood vessel growth in the macula.

Reading can be difficult for people with central vision loss, as damage to the macula affects natural eye movement - making reading slow, tiring, and less enjoyable. Our upcoming webinar will explore a new technique that moves text on a screen in a way that mimics how healthy eyes naturally scan and pause. This technique called Biomimetic Scrolling (BMS) is designed to make reading faster, easier, and more comfortable for people with sight loss.

Why do some people with vision loss experience hallucinations, while others do not?

What are clinical trials? How do they work and what role do they play in improving healthcare? Geraldine Hoad and Sarah Clinton from the Macular Society’s research team join us to discuss the types of trials currently taking place in the UK and how you could get involved.

Thank you for your interest in ‘My Macular and Me’ webinars. These are free to access. All you need to do is complete the form below with your information. You will then be sent monthly updates on speakers, dates and times for the webinars so you can sign up whenever you want to attend. You’ll also hear the latest in research and treatments, advice on living with sight loss, how you can get involved with fundraising, events, products we sell and how we campaign. We’re really looking forward to welcoming you!